Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Profit After Tax (2016 - 2025)

Agios Pharmaceuticals' Profit After Tax history spans 14 years, with the latest figure at -$108.0 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 11.93% year-over-year to -$108.0 million; the TTM value through Dec 2025 reached -$412.8 million, down 161.27%, while the annual FY2025 figure was -$412.8 million, 161.27% down from the prior year.
  • Profit After Tax reached -$108.0 million in Q4 2025 per AGIO's latest filing, down from -$103.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $1.9 billion in Q1 2021 to a low of -$112.0 million in Q2 2025.
  • Average Profit After Tax over 5 years is $63.9 million, with a median of -$90.3 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: soared 4756.01% in 2021, then plummeted 362.66% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$98.6 million in 2021, then surged by 137.05% to $36.5 million in 2022, then tumbled by 362.66% to -$95.9 million in 2023, then fell by 0.61% to -$96.5 million in 2024, then fell by 11.93% to -$108.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Profit After Tax are -$108.0 million (Q4 2025), -$103.4 million (Q3 2025), and -$112.0 million (Q2 2025).